Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis
Phase 2
Completed
- Conditions
- Interventions
- Drug: Finafloxacin 800 mg i.v. once dailyDrug: Finafloxacin placebo i.v. once dailyDrug: Finafloxacin 800 mg tablets once dailyDrug: Finafloxacin placebo tablets once dailyDrug: Ciprofloxacin placebo i.v. twice dailyDrug: Ciprofloxacin 400 mg i.v. twice dailyDrug: Ciprofloxacin placebo oral twice dailyDrug: Ciprofloxacin 500 mg oral twice daily
- First Posted Date
- 2013-08-26
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- MerLion Pharmaceuticals GmbH
- Target Recruit Count
- 225
- Registration Number
- NCT01928433
- Locations
- 🇩🇪
Universitätsklinikum Giessen, Klinik für Urologie, Kinderurologie und Andrologie, Giessen, Germany
Safety and Tolerability of Single and Multiple Intravenous Doses of Finafloxacin in Healthy Subjects
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2013-07-30
- Lead Sponsor
- MerLion Pharmaceuticals GmbH
- Target Recruit Count
- 58
- Registration Number
- NCT01910883
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd, Leeds, United Kingdom
Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- MerLion Pharmaceuticals GmbH
- Target Recruit Count
- 18
- Registration Number
- NCT01907867
- Locations
- 🇺🇸
Pulmonary Associates, PA, Phoenix, Arizona, United States
Effect of Age and Gender on the PK and Tolerability of Finafloxacin
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-07-22
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- MerLion Pharmaceuticals GmbH
- Target Recruit Count
- 40
- Registration Number
- NCT01904162
- Locations
- 🇺🇸
Celerion (formerly MDS Pharmaservices), Tempe, Arizona, United States
Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-07-28
- Last Posted Date
- 2009-06-16
- Lead Sponsor
- MerLion Pharmaceuticals GmbH
- Target Recruit Count
- 30
- Registration Number
- NCT00723502
- Locations
- 🇩🇪
Dr. Hein, Marburg, Germany
Finafloxacin 300 mg Twice a Day (b.i.d.) Versus Ciprofloxacin 250 mg Twice a Day (b.i.d) in Patients With Lower Uncomplicated UTI (uUTI)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-07-28
- Last Posted Date
- 2009-06-11
- Lead Sponsor
- MerLion Pharmaceuticals GmbH
- Target Recruit Count
- 36
- Registration Number
- NCT00722735
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
🇩🇪Medical practice, Dr. J. Hein (Principal Study Investigator), Marburg, Germany
First Time in Man Trial for Friulimicin B
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-06-27
- Last Posted Date
- 2008-07-23
- Lead Sponsor
- MerLion Pharmaceuticals GmbH
- Target Recruit Count
- 31
- Registration Number
- NCT00492271
- Locations
- 🇨🇭
Swiss Pharma Contract Ltd, Basel, Switzerland
First Time in Man Study of Finafloxacin Hydrochloride
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-06
- Last Posted Date
- 2008-07-29
- Lead Sponsor
- MerLion Pharmaceuticals GmbH
- Target Recruit Count
- 95
- Registration Number
- NCT00483158
- Locations
- 🇨🇭
Swiss Pharma Contract Ltd, Basel, Switzerland
© Copyright 2024. All Rights Reserved by MedPath